LUCS/Valitox assay at a glance

- ✓ LUCS is a fluorescence live cell assay
- ✓ First developed as an alternative to animal tests
- ✓ LUCS = VALITOX





- ✓ Based on a photoinduction process protected by patents delivered in Europe (EP2235505 & EP3044569)
- ✓ Measure of cell homeostasis status
- ✓ Different applications in public health
- ✓ Supported by two main publications
- ✓ Submitted to EU ECVAM for regulatory applications




Features & Benefits of LUCS

- ✓ Fully performed on live cells
- $\checkmark \quad \text{Open to multiplexing}$
- ✓ Not limited in terms of cell models (universality)
- ✓ Very robust with a Z'=0,8
- ✓ Very high signal-to-noise ratio (nonspecific fluo easily removed)
- Very simple procedure (+ biosensor, fluo measure, light application, fluo measure)
- ✓ Adapted to optogenetics plate illuminators
- Antioxidant version AOP1: first live cell assay for the measure of intracellular free radical quenching
- ✓ Cost effective
- ✓ Adapted to HTS




Nrf2/LUCS Multiplex analysis



	HS	EC50 (μM)
Nrf2	1.508	2.224
LUCS then Nrf2	1.466	2.356

Uniplex vs multiplex comparison (error bars = 95%CI)





Application notes on industrial plate readers

Cell viability assessment by LUCS assay using EnSight™ multimode

plate reader

Christophe FURGER¹, Camille GIRONDE¹, Mylène RIGAL¹, Wenli DEBORD¹, Carmen MARANGONI² & Brigitte MACHARD²

¹ Anti Oxidant Power – AOP, 78 allées Jean Jaurès, BP 71028, 31000 Toulouse, France
² PerkinElmer - ZA Courtabœuf, 12/14 Avenue de la Baltique, 91140 Villebon sur Yvette, France
Published 15/01/2022



ANTI OXIDANT POWER

Abstract

LUCS (Light Up cell System) is a new viability assay based on the activation of an intracellular

very interesting property for cell biology: its fluorescence quantum yield remains very low (2×10^{-4}) in the culture medium due to free rotation of its two aromatic rings around the




- ✓ Perkin-Elmer (EnSight)
- ✓ Agilent (Cytation)

MATERIAL & METHODS

CLARIOstar Multimode Reader Extern light source (470 nm) AOP "one-step" kits Reagents : - Chloroquine for LUCS

Quercetin for AOP1

HepG2 cells, 75000 cells/well, 96 well plates



perimental protocol

ne different reagent concentrations (500-1.95 μ M, 2X dilutions), in serum-free edium. Cells were incubated for 24 h (LUCS) or 4h (AOP1) at 37°C in 5% CO₂ with each



- ✓ BMG (ClarioStar)
- ✓ Molecular Devices (SpectraMax i3x)
- ✓ Tecan (Spark Cyto)



Consumable kits & HTS robotic platforms

- ✓ Kits of consumables for HTS ~ applications
- ✓ SOP validated
- ✓ International distributor envisaged






470 nm 96/384 well < plate LED light applicator (Teleopto)




Application on skin models


Case of skin models (derm/collagen + mature bioprinted epiderm) POIETIS (2)

191205_Test Poietis peau complète 8µM (RawData-Blanc)





191205_Ratio







In vitro tests for regulatory purposes in EU (situation Year 2020)

Type of targeted toxicity	Available in vitro assays	Partial substitution	Total substitution
Ocular irritation/corrosion	3*	Х	
Acute toxicity	none		
Genotoxicity	5	Х	
Repeated doses	none		
Skin absorption/irritation/corrosion	4	Х	
Skin sensitization	3	Х	
Phototoxicity	1		Х
Endocrine disrupters	5	Х	
Reprotoxicity	none		
Carcinogenicity	none		
Ecotoxicity (poisson, oiseaux)	none		

* + 2 ex-vivo tests: ICE and BCOP



Toxicology Reports 7 (2020) 403-412



Contents lists available at ScienceDirect

Toxicology Reports



journal homepage: www.elsevier.com/locate/toxrep

Use of LUCS (Light-Up Cell System) as an alternative live cell method to predict human acute oral toxicity



C. Gironde, C. Durour, C. Furger*

Anti Oxidant Power, AOP/MH2F team, LAAS/CNRS, 7 avenue du Colonel Roche, BP 54200, Toulouse Cedex, 31031, France

ARTICLE INFO

Keywords: Toxicity testing Alternative methods Non-animal testing Basal cytotoxicity

ABSTRACT


LUCS (Light-Up Cell System) is a new live cell test that allows assessment of a cell's homeostasis and its alteration by a toxic agent. To evaluate the effectiveness of LUCS as an alternative test method for acute oral toxicity, we compared $EC_{50}s$ determined in HepG2 cells treated with 53 chemicals selected from the ACuteTox EU database with corresponding human blood $LC_{50}s$ derived from human acute poisoning cases. Linear regression analysis showed that LUCS results predict human data to 69 %. Rodent oral $LD_{50}s$ and LUCS $EC_{50}s$ were then correlated to human $LC_{50}s$ using shared data sets. Linear regression analyses comparing LUCS and animal data clearly showed that LUCS always predicts human toxicity better than animal data do.

These successful prediction values prompted us to simplify the LUCS test, adapting it to regulatory and high throughput applications, resulting in a new protocol with consistent dose-response profiles and $EC_{50}s$.

This study demonstrates that the LUCS test method could be relevant for assessing human acute oral toxicity with a simplified protocol adapted to commercially available fluorescence readers. We suggest that this new alternative method can be used for acute systemic toxicity testing in combination with other tests under European REACH and other regulations, wherever pertinent alternative methods are still lacking.




Human acute oral toxicity





LUCS EC_{50} s vs Human LC_{50} s





LUCS EC₅₀s and Animal LD₅₀s vs Human LD₅₀s

Comparison	n	Test	R² (test vs human)	Slope	Intercept
LUCS & rat ^b data	37	LUCS (HepG2 cells)	0.670	0.960	- 0.698
		Rat	0.504	0.971	- 1.089
3 LUCS & rat ^c data	35	LUCS (HepG2 cells)	0.695	1.042	- 0.414
		Rat	0.579	1.138	- 0.651
LUCS & mouse ^c data	30	LUCS (HepG2 cells)	0.753	1.140	- 0.200
		Mouse	0.537	1.279	- 0.324

b) Kinsner-Ovaskainen A., Prieto P., Stanzel S., Kopp-Schneider A. (2013)

c) Hoffmann S., Kinsner-Ovaskainen A., Prieto P., Mangelsdorf I., Bieler C., Cole T. (2010)

LUCS always predicts human toxicity better than animal-based assays do



Main comments from EURL ECVAM for our pre-submission TM2021-01 (15 march 2022)

Claims	ECVAM position
Relevance to measure cell homeostasis	ОК
Within Lab Reproducibility (WLR)	CV values seem to indicate good WLR but raw data were not provided
Between Lab Reproducibility (BLR)	Limited set of data - Difficult to conclude
Suitability to HTS	ОК
Prediction model	Provided but not clear how it can be used in regulatory context
Positive impact on the 3Rs	Information provided is not enough to make any judgement
Metabolic competence addressed using Upcyte cells in relation to OECD GD 129	The lack of metabolic competence (bio-activation and detoxification) could apparently be addressed by applying LUCS to Upcyte cells. However, not enough evidence is provided to make any judgement
Multiplexing (use prior to OECD TG 442D)	A clear comparison with other methods is not provided - Waiting for the publication
Use in OECD GD 129	Our interpretation is that the LUCS test method may be a similar method to the 3T3 NRU
Integrating LUCS in defined approaches (DA)	Yes, good correlations, R2 and regression slope values, good base for the claim but not enough data is provided to make any judgement



Conclusion

Applicability of LUCS/Valitox as an alternative method to animal testing to various contexts:

- Can be applied by big pharma companies for their upstream research (validated for HTS, low cost, open to multiplexing, adapted to robotic platforms, excellent Z', very informative with EC₅₀ determination)
- Can be applied by nutraceutics and food/dietary/nutritional supplement companies either for cytotoxicity or antioxidant studies
- ✓ Regulatory purposes : the winning strategy has yet to be found !



Valitox – Next steps

- 1. Organotypic cultures
- 2. hiPSCs
 - 3. Organs-on-Chips

